1. Home
  2. CRSP vs TPH Comparison

CRSP vs TPH Comparison

Compare CRSP & TPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • TPH
  • Stock Information
  • Founded
  • CRSP 2013
  • TPH 2009
  • Country
  • CRSP Switzerland
  • TPH United States
  • Employees
  • CRSP N/A
  • TPH N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • TPH Homebuilding
  • Sector
  • CRSP Health Care
  • TPH Consumer Discretionary
  • Exchange
  • CRSP Nasdaq
  • TPH Nasdaq
  • Market Cap
  • CRSP 3.4B
  • TPH 2.7B
  • IPO Year
  • CRSP 2016
  • TPH N/A
  • Fundamental
  • Price
  • CRSP $37.77
  • TPH $29.57
  • Analyst Decision
  • CRSP Buy
  • TPH Buy
  • Analyst Count
  • CRSP 19
  • TPH 5
  • Target Price
  • CRSP $74.35
  • TPH $43.00
  • AVG Volume (30 Days)
  • CRSP 2.4M
  • TPH 1.2M
  • Earning Date
  • CRSP 05-07-2025
  • TPH 04-24-2025
  • Dividend Yield
  • CRSP N/A
  • TPH N/A
  • EPS Growth
  • CRSP N/A
  • TPH 40.00
  • EPS
  • CRSP N/A
  • TPH 4.83
  • Revenue
  • CRSP $37,314,000.00
  • TPH $4,492,870,000.00
  • Revenue This Year
  • CRSP $51.35
  • TPH N/A
  • Revenue Next Year
  • CRSP $282.16
  • TPH $6.89
  • P/E Ratio
  • CRSP N/A
  • TPH $6.12
  • Revenue Growth
  • CRSP N/A
  • TPH 20.93
  • 52 Week Low
  • CRSP $30.04
  • TPH $27.90
  • 52 Week High
  • CRSP $67.88
  • TPH $47.78
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 49.46
  • TPH 41.81
  • Support Level
  • CRSP $36.74
  • TPH $28.60
  • Resistance Level
  • CRSP $40.13
  • TPH $29.80
  • Average True Range (ATR)
  • CRSP 2.67
  • TPH 1.44
  • MACD
  • CRSP 0.72
  • TPH -0.11
  • Stochastic Oscillator
  • CRSP 76.62
  • TPH 36.38

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About TPH Tri Pointe Homes Inc.

Tri Pointe Homes Inc is an American construction company that focuses on residential construction. The company designs and builds single-family homes and condominiums through its portfolio of six regional housing brands. Its largest regional brands include Maracay Homes, which operates in Arizona, and TRI Pointe and Pardee Homes, which operate in California, Nevada, and Colorado. From a geographic perspective, California is TRI Pointe's largest source of revenue, followed by Arizona and Nevada. The company also operates in Texas, Oregon, and Virginia. TRI Pointe completes approximately 4,000 homes annually with an average selling price around $500,000. TRI Pointe also is involved in the sale and development of land.

Share on Social Networks: